Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection (Q45111047)

9 December 2017

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection (English)

1 reference

9 December 2017

0 references

1 reference

ChEBI release 2020-05-28

Avery RK

1

1 reference

9 December 2017

Bolwell BJ

2

1 reference

9 December 2017

Yen-Lieberman B

3

1 reference

9 December 2017

Lurain N

4

1 reference

9 December 2017

Waldman WJ

5

1 reference

9 December 2017

Longworth DL

6

1 reference

9 December 2017

Taege AJ

7

1 reference

9 December 2017

Mossad SB

8

1 reference

9 December 2017

Kohn D

9

1 reference

9 December 2017

Long JR

10

1 reference

9 December 2017

Curtis J

11

1 reference

9 December 2017

Kalaycio M

12

1 reference

9 December 2017

Pohlman B

13

1 reference

9 December 2017

Williams JW

14

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Bone Marrow Transplantation

9 December 2017

1 reference

9 December 2017

34

1 reference

9 December 2017

12

1 reference

9 December 2017

1071-1075

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704694

9 December 2017

0 references

cites work

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Cytomegalovirus (CMV) resistance to antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Cidofovir in the treatment of cytomegaloviral disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Experiences with leflunomide in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Serious liver disease in a patient receiving methotrexate and leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704694

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704694

1 reference

Dimensions Publication ID

9 December 2017

0 references

1 reference